Roche has started a Phase III clinical trial to assess its Actemra/RoActemra in combination with Gilead Sciences’ remdesivir to treat hospitalised Covid-19 patients with severe pneumonia.
Named REMDACTA, the randomised, double-blind, multi-centre trial will compare the safety and efficacy of the combination to remdesivir plus placebo.
Go deeper with GlobalData
Expected to commence patient enrolment next month, the study is designed to involve about 450 patients worldwide, including in the US, Europe and Canada.
